Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2009

Fluofarma Teams Up with Roche to Develop Hepatotoxicity Tools

  • Fluofarma signed a multiyear collaboration agreement with Roche focused on developing new tools for predicting the hepatotoxicity of early-stage drug candidates. The companies aim to develop miniaturized cell-based assays using high-throughput flow cytrometry along with computational models for predicting hepatotoxicity and safety profiling of compounds in liver cells.

    Fluofarma platforms include automated confocal microscopy, automated flow cytometry, as well as laser scanning cytometry and combine cell-based assays with large-scale analysis. The company claims its  technologies enable the simultaneous functional analysis of several molecular events in single cells.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »